Advicenne SA (DE:3MM)
FRANKFURT:3MM
3MM Stock Chart & Stats
€1.67
€0.03(1.75%)
At close: 4:00 PM EST
€1.67
€0.03(1.75%)
Day’s Range― - ―
52-Week Range€0.81 - €2.20
Previous CloseN/A
Volume0.00
Average Volume (3M)53.00
Market Cap
€16.54M
Enterprise Value€30.38M
Total Cash (Recent Filing)€1.34M
Total Debt (Recent Filing)€19.00M
Price to Earnings (P/E)―
Beta0.55
Next Earnings
Sep 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.72
Shares Outstanding14,609,619
10 Day Avg. Volume61
30 Day Avg. Volume53
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-0.87
Price to Sales (P/S)3.81
P/FCF Ratio-5.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.21
Revenue Forecast (FY)€7.20M
Bulls Say, Bears Say
Bulls Say
Proprietary Specialty ProductOwning a marketed, proprietary formulation (Sibnayal®) gives Advicenne a durable commercial foothold in its rare-kidney niche. Prescription drug sales to identified patient populations produce recurring demand and create a base revenue stream that can scale as diagnosis and market access expand.
Improving Gross ProfitabilityA shift to positive gross margins indicates improving unit economics from product sales or manufacturing efficiency. Sustained gross profit can support reinvestment, reduce reliance on financing, and is a prerequisite for eventual operating profit if fixed costs and commercial scale are managed.
Focused Rare-disease Market PositionConcentrating on rare renal indications creates high barriers to competition, specialist prescribing patterns, and favorable reimbursement dynamics. This structural positioning supports pricing power and steady long-term demand from a defined patient population, aiding revenue visibility.
Bears Say
Negative Equity / Fragile Balance SheetPersistent negative equity signals solvency and capitalization issues, limiting borrowing capacity and strategic flexibility. Over months this raises refinancing and covenant risk, forcing potentially dilutive financing or asset sales to sustain operations and commercialization expansion.
Ongoing Cash BurnConsistent negative operating and free cash flow means the company depends on external funding to run operations and commercialize Sibnayal®. Over 2–6 months this elevates financing risk, may constrain marketing or geographic rollouts, and can pressure strategic choices.
Small, Volatile And Declining RevenueA small, inconsistent revenue base that turned negative in 2025 undermines scale economics and makes fixed commercial costs harder to absorb. Without stable top-line growth, margin gains may be fragile and the company remains vulnerable to funding gaps and competitive or reimbursement setbacks.
Advicenne SA News
3MM FAQ
What was Advicenne SA’s price range in the past 12 months?
Advicenne SA lowest stock price was €0.81 and its highest was €2.20 in the past 12 months.
What is Advicenne SA’s market cap?
Advicenne SA’s market cap is €16.54M.
When is Advicenne SA’s upcoming earnings report date?
Advicenne SA’s upcoming earnings report date is Sep 17, 2026 which is in 96 days.
How were Advicenne SA’s earnings last quarter?
Advicenne SA released its earnings results on Mar 26, 2026. The company reported -€0.314 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.314.
Is Advicenne SA overvalued?
According to Wall Street analysts Advicenne SA’s price is currently Overvalued.
Does Advicenne SA pay dividends?
Advicenne SA does not currently pay dividends.
What is Advicenne SA’s EPS estimate?
Advicenne SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Advicenne SA have?
Advicenne SA has 14,609,619 shares outstanding.
What happened to Advicenne SA’s price movement after its last earnings report?
Advicenne SA reported an EPS of -€0.314 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 15.881%.
Which hedge fund is a major shareholder of Advicenne SA?
Currently, no hedge funds are holding shares in DE:3MM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Advicenne SA
Advicenne S.A. operates as a specialized pharmaceutical firm, focusing on the innovation and commercialization of therapeutic solutions for various kidney-related disorders. The company's primary offering, Sibnayal, targets both distal renal tubular acidosis and cystinuria. Established in 2007, Advicenne S.A. maintains its principal offices in Paris, France.